Zacks Investment Research on MSN
Merck's non-oncology drugs Q4 performance: What to expect
As Merck MRK is gearing up to report its fourth-quarter and full-year 2025 results on Feb. 3, investors' focus is likely to ...
Zacks.com on MSN
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained ...
Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, TD Cowen ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD ...
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results